Cullinan Therapeutics Inc
Company Profile
Business description
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Contact
One Main Street
Suite 1350
CambridgeMA02142
USAT: +1 617 410-4650
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
109
Stocks News & Analysis
stocks
Overvalued ASX share has overly ambitious profit target
stocks
7 undervalued US stocks that crushed earnings
stocks
Undervalued ASX share hitting on all cylinders
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,034.90 | 130.50 | -1.42% |
| CAC 40 | 8,352.00 | 16.91 | -0.20% |
| DAX 40 | 26,598.64 | 151.31 | -0.57% |
| Dow JONES (US) | 51,608.17 | 739.38 | -1.41% |
| FTSE 100 | 10,881.55 | 21.01 | -0.19% |
| HKSE | 23,753.84 | 116.24 | 0.49% |
| NASDAQ | 24,509.76 | 626.52 | -2.49% |
| Nikkei 225 | 59,021.82 | 640.20 | -1.07% |
| NZX 50 Index | 14,266.55 | 37.22 | -0.26% |
| S&P 500 | 7,416.59 | 145.08 | -1.92% |
| S&P/ASX 200 | 8,917.80 | 126.90 | -1.40% |
| SSE Composite Index | 3,602.57 | 31.78 | -0.87% |